CTOs on the Move

Ion Beam Applications

www.iba-worldwide.com

 
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The Company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1200 people worldwide, IBA ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

PL Developments

PL Developments is a Westbury, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NuWave

NuWave is a Upland, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Elmore Medical Center Foundation Inc

Elmore Medical Center Foundation Inc is a Mountain Home, ID-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Groups360

Groups360™️ was founded in 2014 with the goal of simplifying and transforming the ways meetings are booked. The company`s search engine, GroupSync™️, using its proprietary matching algorithms designed specifically for meeting planners, has helped place thousands of events at the right venue, saving planners time and money. GroupSync`s price predictor tool delivers improved transparency, reducing time and effort required to book meetings for both the hotel and the planner. Groups360`s management team has decades of experience in the meetings and events industry and provides the right mix of technology and experienced advisors. Using GroupSync, planners can search more than 200,000 properties in 225 countries and territories.

Imagin Medical

Imagin Medical is developing imaging solutions for the early detection of cancer through the use of endoscopes. The Company believes it will radically improve the way physicians detect cancer. Imagin`s initial target market is bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due to a greater than 50% recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced, ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors.